LLL-3, a STAT3 inhibitor, represses BCR-ABL-positive cell proliferation, activates apoptosis and improves the effects of Imatinib mesylate

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 6, 2010, Pages 1039-1046

  Mencalha, Andre Luiz ^a,b   Rocher, B Du ^a,b   Salles, D ^a,b   Binato, R ^a,b   Abdelhay, E ^b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

BCR ABL; Imatinib; LLL 3; STAT3

Indexed keywords

ANTHRACENE DERIVATIVE; BCR ABL PROTEIN; CASPASE 3; CASPASE 7; DNA; FLUORESCEIN ISOTHIOCYANATE; IMATINIB; LIPOCORTIN 5; LLL 3; STAT3 PROTEIN; UNCLASSIFIED DRUG; ANTHRAQUINONE DERIVATIVE; ANTINEOPLASTIC AGENT; LLL 3 COMPOUND; LLL-3 COMPOUND; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL PROLIFERATION; CELL STRAIN K 562; CELL VIABILITY; CONTROLLED STUDY; DNA CONTENT; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENTIATION; DRUG RESPONSE; ENZYME ACTIVATION; HUMAN CELL; PRIORITY JOURNAL; STAINING; CELL LINE; CELL SURVIVAL; DOSE RESPONSE; DRUG ANTAGONISM; HUMAN; IC 50; METABOLISM; TUMOR CELL LINE;

ANTHRAQUINONES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CASPASE 7; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME ACTIVATION; FUSION PROTEINS, BCR-ABL; HUMANS; INHIBITORY CONCENTRATION 50; K562 CELLS; PIPERAZINES; PYRIMIDINES; STAT3 TRANSCRIPTION FACTOR;

EID: 77951884693     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1109-3     Document Type: Article

References (36)

1. Melo JV, Chuah C (2008) Novel agents in CML therapy: tyrosine kinase inhibitors and beyond. Hematol Am Soc Hematol Educ Program 427-435
2. Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M (2003) Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med 138:819-830
3. Chai SK, Nichols GL, Rothman P (1997) Constitutive activation of JAKs and STATs in BCR-ABL-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol 159:4720-4728
4. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA (2004) JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18:189-218
5. Yanada M, Ohno R, Naoe T (2008) Recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Int J Hematol. doi:10.1007/s12185-008-0223-z
6. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037
7. Roskoski R Jr (2003) STI-571: an anticancer protein-tyrosine kinase inhibitor. Biochem Biophys Res Commun 309:709-717
8. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042
9. Deininger M (2008) Resistance and relapse with imatinib in CML: causes and consequences. J Natl Compr Canc Netw 2:S11-S21
10. Weisberg E, Griffin JD (2003) Resistance to imatinib (Glivec) : update on clinical mechanisms. Drug Resist Updat 6:231-238
11. Weisberg E, Banerji L, Wright RD, Barrett R, Ray A, Moreno D, Catley L, Jiang J, Hall-Meyers E, Sauveur-Michel M, Stone R, Galinsky I, Fox E, Kung AL, Griffin JD (2008) Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL-and mutant FLT3-expressing cells. Blood 111:3723-3734
12. Coppo P, Flamant S, De Mas V, Jarrier P, Guillier M, Bonnet ML, Lacout C, Guilhot F, Vainchenker W, Turhan AG (2006) BCR-ABL activates STAT3 via JAK and MEK pathways in human cells. Br J Haematol 134:171-179
13. Coppo P, Dusanter-Fourt I, Millot G, Nogueira MM, Dugray A, Bonnet ML, Mitjavila-Garcia MT, Le Pesteur D, Guilhot F, Vainchenker W, Sainteny F, Turhan AG (2003) Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells. Oncogene. 22:4102-4110
14. Weber-Nordt RM, Egen C, Wehinger J, Ludwig W, Gouilleux-Gruart V, Mertelsmann R, Finke J (1996) Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood 88:809-816
15. Benekli M, Xia Z, Donohue KA, Ford LA, Pixley LA, Baer MR, Baumann H, Wetzler M (2002) Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood 99:252-257
16. Yared MA, Khoury JD, Medeiros LJ, Rassidakis GZ, Lai R (2005) Activation status of the JAK/STAT3 pathway in mantle cell lymphoma. Arch Pathol Lab Med 129:990-996
17. Chen CL, Cen L, Kohout J, Hutzen B, Chan C, Hsieh FC, Loy A, Huang V, Cheng G, Lin J (2008) Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival. Mol Cancer 7:78
18. Lieblein JC, Ball S, Hutzen B, Sasser AK, Lin HJ, Huang TH, Hall BM, Lin J (2008) STAT3 can be activated through paracrine signaling in breast epithelial cells. BMC Cancer 8:302
19. Abdulghani J, Gu L, Dagvadorj A, Lutz J, Leiby B, Bonuccelli G, Lisanti MP, Zellweger T, Alanen K, Mirtti T, Visakorpi T, Bubendorf L, Nevalainen MT (2008) Stat3 promotes metastatic progression of prostate cancer. Am J Pathol 172:1717-1728
20. Liu B, Ren Z, Shi Y, Guan C, Pan Z, Zong Z (2008) Activation of signal transducers and activators of transcription 3 and overexpression of its target gene Cyclin D1 in laryngeal carcinomas. Laryngoscope 118:1976-1980
21. Germain D, Frank DA (2007) Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin Cancer Res 13:5665-5669
22. Fletcher S, Turkson J, Gunning PT (2008) Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein. Chem Med Chem 3:1159-1168
23. Aziz MH, Dreckschmidt NE, Verma AK (2008) Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer. Cancer Res 68:9024-9032
24. Hao W, Hu Y, Niu C, Huang X, Chang CP, Gibbons J, Xu J (2008) Discovery of the catechol structural moiety as a Stat3 SH2 domain inhibitor by virtual screening. Bioorg Med Chem Lett 18:4988-4992
25. Bhasin D, Cisek K, Pandharkar T, Regan N, Li C, Pandit B, Lin J, Li PK (2008) Design, synthesis, and studies of small molecule STAT3 inhibitors. Bioorg Med Chem Lett 18:391-395
26. Sirard C, Laneuville P, Dick JE (1994) Expression of bcr-abl abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism. Blood 83:1575-1585
27. Nicoletti I, Migliorati G, Pagliaccil MC, Grignani F, Riccardi C (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139:271-279
28. Turkson J, Kim JS, Zhang S, Yuan J, Huang M, Glenn M, Haura E, Sebti S, Hamilton AD, Jove R (2004) Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther 3:261-269 (Pubitemid 39193701)
29. Lizard G, Miguet C, Gueldry S, Monier S, Gambert P (1997) Flow cytometry measurement of DNA fragmentation in the course of cell death via apoptosis. New techniques for evaluation of DNA status for the pathologist. Ann Pathol 17:61-66
30. Raguz S, Yagüe E (2008) Resistance to chemotherapy: new treatments and novel insights into an old problem. Br J Cancer 99:387-391
31. Song H, Wang R, Wang S, Lin J (2005) A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci USA 102:4700-4705
32. Xie SQ, Hu GQ, Zhang ZQ, Xu M, Ji BS (2008) Anti-tumour effects of HL-37, a novel anthracene derivative, in vivo and in vitro. J Pharm Pharmacol 60:213-219
33. Weisberg E, Griffin JD (2003) Resistance to imatinib (Glivec) : update on clinical mechanisms. Drug Resist Updat 6:231-238
34. Aggarwal BB, Sethi G, Ahn KS, Sandur SK, Pandey MK, Kunnumakkara AB, Sung B, Ichikawa H (2006) Targeting signaltransducer-and-activator-of-transcription- 3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci 1091:151-169
35. Bewry NN, Nair RR, Emmons MF, Boulware D, Pinilla-Ibarz J, Hazlehurst LA (2008) Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol Cancer Ther 7:3169-3175
36. Ye D, Wolff N, Li L, Zhang S, Ilaria RL Jr (2006) STAT5 signaling is required for the efficient induction and maintenance of CML in mice. Blood 7:4917-4925